Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
GMAB or RGEN: Which Is the Better Value Stock Right Now?
12:46pm, Wednesday, 16'th Apr 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value
Repligen Appoints Jacob Johnson As Vice President Investor Relations
07:30am, Tuesday, 08'th Apr 2025
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
05:15am, Tuesday, 08'th Apr 2025
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Repligen: Ongoing Bioprocessing Market Recovery
07:52am, Thursday, 20'th Mar 2025
I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in no
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
01:26pm, Tuesday, 04'th Mar 2025
On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
07:30am, Tuesday, 04'th Mar 2025
Portfolio includes PAT devices for real-time process monitoring, control and analysis Portfolio includes PAT devices for real-time process monitoring, control and analysis
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
11:35am, Friday, 21'st Feb 2025
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript
02:53pm, Thursday, 20'th Feb 2025
Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President an
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
02:00pm, Thursday, 20'th Feb 2025
Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents.
Repligen's Q4 Slightly Tops Expectations
11:25am, Thursday, 20'th Feb 2025
Repligen (RGEN 7.92%), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimat
Repligen (RGEN) Beats Q4 Earnings Estimates
09:45am, Thursday, 20'th Feb 2025
Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago.
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
07:30am, Tuesday, 11'th Feb 2025
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET
HRMY vs. RGEN: Which Stock Is the Better Value Option?
12:41pm, Thursday, 30'th Jan 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks present
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
04:20am, Wednesday, 29'th Jan 2025
Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Repligen price target lowered to $180 from $240 at H.C. Wainwright
06:06am, Thursday, 23'rd Jan 2025
H.C. Wainwright lowered the firm's price target on Repligen to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the co
